Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

BioLineRx (BLRX) EBT: 2012-2024

Historic EBT for BioLineRx (BLRX) over the last 13 years, with Dec 2024 value amounting to -$11.3 million.

  • BioLineRx's EBT rose 45.04% to -$2.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$7.7 million, marking a year-over-year increase of 80.04%. This contributed to the annual value of -$11.3 million for FY2024, which is 76.25% up from last year.
  • BioLineRx's EBT amounted to -$11.3 million in FY2024, which was up 76.25% from -$47.5 million recorded in FY2023.
  • BioLineRx's EBT's 5-year high stood at -$11.3 million during FY2024, with a 5-year trough of -$47.5 million in FY2023.
  • For the 3-year period, BioLineRx's EBT averaged around -$28.6 million, with its median value being -$27.0 million (2022).
  • Its EBT has fluctuated over the past 5 years, first plummeted by 76.03% in 2023, then spiked by 76.25% in 2024.
  • Yearly analysis of 5 years shows BioLineRx's EBT stood at -$21.3 million in 2020, then declined by 11.61% to -$23.8 million in 2021, then dropped by 13.58% to -$27.0 million in 2022, then crashed by 76.03% to -$47.5 million in 2023, then spiked by 76.25% to -$11.3 million in 2024.